- Home
- ZION vs BMRN Comparison
ZION vs BMRN Comparison
Compare ZION & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZION | BMRN |
|---|---|---|
| Founded | 1873 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 10.0B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | ZION | BMRN |
|---|---|---|
| Price | $64.08 | $59.81 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 20 | 21 |
| Target Price | $63.15 | ★ $89.86 |
| AVG Volume (30 Days) | ★ 2.1M | 2.0M |
| Earning Date | 01-20-2026 | 02-20-2026 |
| Dividend Yield | ★ 2.76% | N/A |
| EPS Growth | 21.41 | ★ 59.53 |
| EPS | ★ 6.01 | 2.68 |
| Revenue | ★ $3,314,000,000.00 | $3,094,001,000.00 |
| Revenue This Year | $8.48 | $13.53 |
| Revenue Next Year | $4.37 | $9.69 |
| P/E Ratio | ★ $10.84 | $21.56 |
| Revenue Growth | 8.37 | ★ 12.39 |
| 52 Week Low | $39.32 | $50.76 |
| 52 Week High | $66.18 | $73.51 |
Technical Indicators
Market Signals| Indicator | ZION | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 65.43 | 61.55 |
| Support Level | $57.77 | $56.87 |
| Resistance Level | $66.18 | $58.43 |
| Average True Range (ATR) | 1.54 | 1.53 |
| MACD | 0.45 | 0.21 |
| Stochastic Oscillator | 75.91 | 82.36 |
Price Performance
Historical ComparisonAbout ZION Zions Bancorporation N.A.
Zions Bancorp is a US regional bank with around $90 billion in total assets as of Sept. 30, 2025. Headquartered in Salt Lake City, Utah, Zions' branch network is in the Western and Southwestern United States and includes seven affiliate banks in these markets. The bank has a heavy focus on small and midsize commercial banking.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.